YP1A.F · Immutep Limited

About

About Immutep Limited

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.